GLOW common uses, half-life, side effects and more

GLOW is a premixed injectable blend of GHK-Cu, BPC-157, and TB-500 sold as a single vial. People use it for skin quality, post-procedure recovery, scar remodeling, and soft-tissue recovery. GHK-Cu is a copper peptide used for skin, hair, and cosmetic repair. BPC-157 and TB-500 are soft-tissue peptides used for tendon, ligament, muscle, and wound recovery. The injectable blend is not an approved medicine and is sold gray-market as a research chemical.

• Skin quality and cosmetic recovery
• Post-procedure recovery after microneedling, laser, or minor procedures
• Scar remodeling and wound healing
• Tendon, ligament, muscle, and joint recovery
• Hair and scalp appearance
• Soft-tissue repair

Daily to two or three times weekly across 4 to 8 week cycles

The dosing that circulates for GLOW reconstitutes the 70 mg 50/10/10 vial in 2 to 3 mL of bacteriostatic water for a fixed 10-unit (0.10 mL) subcutaneous draw once daily. It anchors on that draw rather than a milligram number. The water volume decides what the draw weighs. A 3 mL mix makes it about 2.3 mg of total blend. A 2 mL mix makes it about 3.5 mg. That delivers 1.7 to 2.5 mg GHK-Cu, 330 to 500 mcg BPC-157, and 330 to 500 mcg TB-500 per injection. Some guides push the target higher toward about 3 mg of GHK-Cu. The GHK-Cu amount runs at or above common standalone daily use of 1 to 2 mg. The BPC-157 amount reaches the top of its standalone 250 to 500 mcg once-daily range. A daily schedule delivers about 2.3 to 3.5 mg of TB-500 per week. That sits in the upper half of standalone TB-500's usual 2 to 5 mg total. It arrives as small daily amounts rather than the twice-weekly bolus standalone users take.

• Each 1 mg of total blend from the 50/10/10 vial delivers 714 mcg GHK-Cu, 143 mcg BPC-157, and 143 mcg TB-500 at the fixed 5:1:1 ratio
• The per-dose amounts depend on the exact label because some sellers ship other formats such as a 30/10/10 vial at a 3:1:1 ratio or an oral capsule
• Running the three as separate vials instead of the premix restores independent scheduling for each peptide
• Product labels reading TB-500 may hold either the short Ac-LKKTETQ fragment or full-length thymosin beta-4
• KLOW is this blend plus KPV and should not be logged as GLOW
• GHK-Cu is often cycled about 30 days on and 30 days off to limit copper exposure

No combination pharmacokinetic study exists. The three components clear at different rates. BPC-157 clears from animal plasma in under 30 minutes and has no human measurement. Injected GHK-Cu has no measured human plasma half-life by any route. No one has measured a half-life for the injected TB-500 fragment either.

GHK-Cu solution is normally blue to blue-violet from the copper complex. A loss of that blue color can signal degradation. A colorless product is a sign it is not GHK-Cu. Protect the powder and solution from light, heat, and chelators such as EDTA.

• Injection-site redness, swelling, bruising, or soreness that can begin hours after the shot
• Skin breakouts, welts, or lumps at injection sites that sometimes persist for weeks
• Headache, nausea, dizziness, fatigue, lightheadedness, or mental fog reported by users
• Copper excess can cause abdominal pain, nausea, vomiting, jaundice, unusual bruising, or anemia

• GHK-Cu

  1.7 to 2.5 mg per daily dose from the 50/10/10 mg vial

• BPC-157

  330 to 500 mcg per daily dose from the 50/10/10 mg vial

• TB-500

  330 to 500 mcg per daily dose from the 50/10/10 mg vial

GHK-Cu is the tripeptide GHK bound to copper. Copper is a required cofactor for the enzymes that cross-link collagen and elastin and defend cells against oxidation. Skin and wound-cell models link GHK-Cu to fibroblast activity, matrix turnover, and inflammatory signaling. BPC-157 has no identified receptor and no settled human mechanism. Animal and cell work reports that it raises the receptor VEGFR2 without raising VEGF-A itself and moves tendon fibroblasts. Its effect on new blood vessels runs in both directions across tissues rather than in one. TB-500 is the acetylated LKKTETQ fragment of thymosin beta-4 and keeps the parent protein's actin-binding site. Laboratory work shows the fragment driving cell migration and new vessel growth. The anti-inflammatory parts of thymosin beta-4 sit in regions the fragment lacks. The stated rationale for the blend combines matrix remodeling, repair signaling, and cell-migration biology. No study shows the combination outperforms any single component.

Direct evidence for the GLOW combination is very low. No human trial, animal study, pharmacokinetic study, or case series of GHK-Cu plus BPC-157 plus TB-500 together was found. GHK-Cu has route-specific evidence that is strongest for topical cosmetic and wound use. Injected GHK-Cu has never been given to a person in a published study. BPC-157 evidence is mostly animal and cell work with minimal uncontrolled human data. Most of it traces to a single research group with little independent replication. TB-500 evidence is weaker still. Almost all of it is for full-length thymosin beta-4 rather than the fragment. No published human study has given the fragment itself to people for healing. The 50/10/10 ratio and the circulating dose both come from the market and dosing-guide websites rather than from any dose-finding study or clinical protocol.

• Tested athletes should treat the whole blend as prohibited because BPC-157 and TB-500 are both banned in sport at all times
• The injectable blend is not FDA approved and FDA has flagged injectable GHK-Cu, BPC-157, and TB-500 in compounding for limited human safety, immunogenicity, and peptide-impurity concerns
• People with active or recent cancer, unexplained masses, or proliferative retinopathy should avoid the blend because BPC-157 has no carcinogenicity study and thymosin beta-4 can promote the cell migration and new vessels that tumors use
• Wilson disease, copper overload, significant liver or kidney disease, unexplained anemia, or copper allergy make injected GHK-Cu riskier because a needle bypasses the gut limits on copper
• Blood thinners, clotting disorders, or abnormal liver markers need clinician guidance because animal BPC-157 studies found clotting-time and liver-marker changes
• Pregnancy, breastfeeding, fertility, pediatric use, and long-term repeated cycles have no adequate safety data for any component